Lauren Sosdorf
Nurse Practitioner · Zephyrhills, FLNPI 1083031082
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,151 of the $58,943 with a category attached, or 90.2%. 33 manufacturers reported payments, led by Insulet Corporation at 56.7% of the total. 2025 is the largest year on record at $41,309, more than ten times the $494 reported in 2021. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $178.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$33K
- Tandem Diabetes Care, Inc.$21K
- Lilly USA, LLC$715
- Sanofi-aventis U.S. LLC$513
- Dexcom, Inc.$440
- Novo Nordisk$433
- plus $3K from 27 others
What the payments were for
- Consulting fees$2500%
- Speaking & faculty fees$53,15190%
- Food & beverage$5,5309%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 56 | $33,404 |
| Tandem Diabetes Care, Inc. | 41 | $20,666 |
| Lilly USA, LLC | 43 | $715 |
| Sanofi-aventis U.S. LLC | 22 | $513 |
| Dexcom, Inc. | 18 | $440 |
| Novo Nordisk | 31 | $433 |
| BETA Bionics, Inc. | 7 | $355 |
| Bayer | 15 | $316 |
| Sequel Med Tech, LLC | 3 | $292 |
| Boehringer Ingelheim | 11 | $269 |
| Corcept Therapeutics | 12 | $227 |
| Xeris Pharmaceuticals, Inc. | 13 | $191 |
| Amneal Pharmaceuticals LLC | 7 | $137 |
| Merck | 6 | $101 |
| AstraZeneca | 4 | $88 |
| Neurocrine Biosciences, Inc. | 3 | $83 |
| Avvisto Therapeutics, LLC | 4 | $80 |
| IBSA Pharma Inc. | 4 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $77 |
| Medtronic | 4 | $65 |
| AbbVie | 4 | $59 |
| Mannkind Corporation | 3 | $52 |
| Madrigal Pharmaceuticals | 2 | $50 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Recordati_rare_diseases_inc. | 2 | $43 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Amgen | 1 | $22 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Vivus LLC | 1 | $16 |
| Abbott | 1 | $16 |
| Nevro Corp. | 1 | $15 |
| Radius Health, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,943 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $87,126 |
| MounjaroTirzepatide | 60 | $84,620 |
| JardianceEmpagliflozin | 100 | $80,561 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $44,429 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $42,327 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $41,120 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 24 | $22,763 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $21,165 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $18,581 |
| FarxigaDapagliflozin Propanediol | 12 | $16,831 |
| Novolog FlexpenInsulin Aspart | 36 | $16,416 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $15,183 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $9,840 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 27 | $9,536 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $9,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $433 | $95,50588 claims |
| Boehringer IngelheimJardiance, Tradjenta | $269 | $88,219114 claims |
| Lilly USA, LLCMounjaro | $715 | $84,62060 claims |
| MerckJanumet Xr, Janumet | $101 | $37,94544 claims |
| AstraZenecaFarxiga | $88 | $16,83112 claims |
| AbbVieSynthroid | $59 | $4,12639 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $137 | $2,550131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Zephyrhills
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
- Jennifer PuleoTampa$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.